Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften E-learning Web-tv Video Audio
Tips voor Mijn BSL
UITGEBREID ZOEKEN
Inloggen
Top
Gepubliceerd in:
Huisartsgeneeskundige oncologie hoofdstuk lezen eerste hoofdstuk lezen

2014 | OriginalPaper | Hoofdstuk

12. Prostaatcarcinoom

Auteurs : Esther Hamoen, Fred Witjes

Gepubliceerd in: Ontwikkelingen in de oncologie

Uitgeverij: Bohn Stafleu van Loghum

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Inleiding

Prostaatcarcinoom is, met een relatief aandeel van 21%, de meest voorkomende vorm van kanker bij Nederlandse mannen. In 2009 kwamen er 10.166 nieuwe patiënten met prostaatcarcinoom bij en overleden er 2492 aan de aandoening.1 De incidentie neemt toe, onder andere vanwege vergrijzing van de bevolking en toegenomen vroegdiagnostiek, maar ook gecorrigeerd voor dergelijke factoren lijkt zich een ‘echte’ stijging van de incidentie voor te doen. Er zullen dus steeds meer mannen voor prostaatcarcinoom worden behandeld.
vorige hoofdstuk Colorectaal carcinoom
volgende hoofdstuk Longcarcinoom
Literatuur
1.
2.
Vicini FA, Martinez A, Hanks G, Hanlon A, Miles B, Kernan K, et al. An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up. Cancer 2002;95:2126–35.PubMedCrossRef
3.
Steinberg GD, Bales GT, Brendler CB. An analysis of watchful waiting for clinically localized prostate cancer. J Urol 1998;159:1431–6.PubMedCrossRef
4.
Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293:2095–101.PubMedCrossRef
5.
Fahmy WE, Bissada NK. Cryosurgery for prostate cancer. Arch Androl 2003;49:397–407.PubMed
6.
7.
Han KR, Belldegrun AS. Third-generation cryosurgery for primary and recurrent prostate cancer. BJU Int 2004;93:14–8.PubMedCrossRef
8.
Beerlage HP, Thuroff S, Madersbacher S, Zlotta AR, Aus G, De Reijke TM, et al. Current status of minimally invasive treatment options for localized prostate carcinoma. Eur Urol 2000;37:2–13.PubMedCrossRef
9.
Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011;59:61–71.PubMedCrossRef
10.
Nguyen CT, Jones JS. Focal therapy in the management of localized prostate cancer. BJU Int 2011;107:1362–8.PubMedCrossRef
11.
Long JP, Bahn D, Lee F, Shinohara K, Chinn DO, Macaluso JN Jr. Five-year retrospective, multi-institutional pooled analysis of cancer-related outcomes after cryosurgical ablation of the prostate. Urology 2001;57:518–23.PubMedCrossRef
12.
Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002;167:528–34.PubMedCrossRef
13.
Kupelian PA, Potters L, Khuntia D, Ciezki JP, Reddy CA, Reuther AM, et al. Radical prostatectomy, external beam radiotherapy < 72 Gy, external radiotherapy > or = 72 Gy, permanent seed implantation or combined seeds/external beam radiotherapy for stage T1-2 prostate cancer. Int J Radiat Oncol Biol Phys 2004;58:25–33.PubMedCrossRef
14.
Bahn DK, Lee F, Badalament R, Kumar A, Greski J, Chernick M. Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology 2002;60:3–11.PubMedCrossRef
15.
Donelly BJ, Saliken JC, Ernst DS, Ali-Ridha N, Brasher PM, Robinson JW, et al. Prospective trial of cryosurgical ablation of the prostate: Five year results. Urology 2002;60:645–9.CrossRef
16.
Han KR, Cohen JK, Miller RJ, Pantuck AJ, Freitas DG, Cuevas CA, et al. Treatment of organ confined prostate cancer with third generation cryosurgery: Preliminary multicenter experience. J Urol 2003;170:1126–30.PubMedCrossRef
17.
Koppie TM, Shinohara K, Grossfeld GD, Presti JC Jr, Carroll PR. The efficacy of cryosurgical ablation of prostate cancer: The University of California, San Francisco experience. J Urol 1999;162:427–32.PubMedCrossRef
18.
De La Taille A, Benson MC, Bagiella E, Burchardt M, Shabsigh A, Olsson CA, et al. Cryoablation for clinically localized prostate cancer using an argon-based system: Complication rates and biochemical recurrence. BJU Int 2000;85:281–6.PubMedCrossRef
19.
Robinson JW, Donnelly BJ, Saliken JC, Weber BA, Ernst S, Rewcastle JC. Quality of life and sexuality of men with prostate cancer 3 years after cryosurgery. Urology 2002;60:12–8.PubMedCrossRef
20.
Robinson JW, Donnelly BJ, Siever JE, Saliken JC, Ernst SD, Rewcastle JC, et al. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer: Quality of life outcomes. Cancer 2009;115:4695–704.PubMedCrossRef
21.
Poissonnier L, Chapelon JY, Rouvière O, Curiel L, Bouvier R, Martin X, et al. Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol 2007;51:381–7.PubMedCrossRef
22.
Uchida T, Shoji S, Nakano M, Hongo S, Nitta M, Murota A, et al. Transrectal high-intensity focused ultrasound for the treatment of localized prostate cancer: Eight-year experience. Int J Urol 2009;16:881–6.PubMedCrossRef
23.
Madersbacher S, Marberger M. High-energy shockwaves and extracorporeal high-intensity focused ultrasound. J Endourol 2003;17:667–72.PubMedCrossRef
24.
Gelet A, Chapelon JY, Bouvier R, Pangaud C, Lasne Y. Local control of prostate cancer by transrectal high intensity focused ultrasound therapy: Preliminary results. J Urol 1999;161:156–62.PubMedCrossRef
Metagegevens
Titel
Prostaatcarcinoom
Auteurs
Esther Hamoen
Fred Witjes
Copyright
2014
Uitgeverij
Bohn Stafleu van Loghum
Boek
Ontwikkelingen in de oncologie

Print ISBN: 978-90-368-0435-6

Elektronisch ISBN: 978-90-368-0436-3

Copyright: 2014

DOI
https://doi.org/10.1007/978-90-368-0436-3_12